Beneficial effects of the dual L- and T-type Ca2+ channel blocker efonidipine on cardiomyopathic hamsters

Circulation Journal

Volumn 71, Issue 12, 2007, Pages 1970-1976

  Suzuki, Shinsuke ^a   Ohkusa, Tomoko ^a   Ono, Katsushige ^a   Sato, Takashi ^a   Yoshida, Masa Aki ^a   Yano, Masafumi ^a   Takebayashi, Satoshi ^b   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OITA UNIVERSITY   (Japan)

Author keywords

Ca2+ channel; Ca2+ channel blocker; Efonidipine; Heart failure; T type Ca2+ channel

Indexed keywords

BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; CALCIUM CHANNEL T TYPE; EFONIDIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY GROWTH; CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; FEMALE; HAMSTER; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART MUSCLE CELL; MALE; NONHUMAN; PATCH CLAMP; PROTEIN EXPRESSION;

ANIMALS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, T-TYPE; CARDIOMYOPATHIES; CRICETINAE; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HEART RATE; MALE; MESOCRICETUS; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PATCH-CLAMP TECHNIQUES;

EID: 37149019025     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1970     Document Type: Article

References (27)

1. 2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993; 73: 777-782.
2. 2+ channels in ventricular cells from hypertrophied rat hearts. J Mol Cell Cardiol 1999; 31: 1617-1625.
3. 2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994; 75: 149-155.
4. 2+ channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res 2000; 46: 442-449.
5. Izumi T, Kihara Y, Sarai N, Yoneda T, Iwanaga Y, Inagaki K, et al. Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro. Circulation 2003; 108: 2530-2535.
6. Ferron L, Capuano V, Ruchon Y, Deroubaix E, Coulombe A, Renaud JF. Angiotensin II signaling pathways mediate expression of cardiac T-type calcium channels. Circ Res 2003; 93: 1241-1248.
7. 2+-release channels during development of heart failure in cardiomyopathic hamsters. Am J Physiol 1998; 274: 111-117.
8. Tawada-Iwata Y, Imanaga T, Yoshida A, Takahashi M, Nakamura H, Shigekawa M. Increased mechanical extraction of T-tubule/junctional SR from cardiomyopathic hamster heart. Am J Physiol 1993; 264: H1447-H1453.
9. Wanger JA, Reynolds LJ, Weisman HF, Dudeck P, Weisfeld ML, Snyder SH. Calcium antagonist receptors in cardiomyopathic hamster: Selective increase in heart, muscle, brain. Science 1986; 232: 515-517.
10. Bazan E, Sole MJ, Schwartz A, Johnson CL. Dihydropyridine receptor binding sites in the cardiomyopathic hamster heart are unchanged from control. J Mol Cell Cardiol 1991; 23: 111-117.
11. Packer M, Kessler PD, Lee WH. Calcium channel blockade in the management of severe chronic congestive heart failure: A bridge too far. Circulation 1987; 75(Suppl V): V-56-V-64.
12. Elkayam U, Amin J, Mehra A, Vasquez J, Weber L, Rahimtoola AH. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with. that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82: 1954-1961.
13. Veninant M, Clozel JP, Hess P, Wolfgang R. Ro 40-5967, in contrast to diltiazem, dose not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991; 17: 277-284.
14. Cingolani OH, Yang XP, Cavasin MA, Carretero OA. Increased systolic performance with diastolic dysfunction in adult spontaneous hypertensive rats. Hypertension 2003; 41: 249-254.
15. Yamada J, Ohkusa T, Mao T, Ueyaina T, Yano M, Kobayashi S, et al. Up-regulation of inositol 1.4.5 trisphosphate receptor expression in atrial tissue in patients with chronic atrial fibrillation. J Am Coll Cardiol 2001; 37: 1111-1119.
16. McRory JL, Santi CM, Hamming KSC, Mezeyova J, Sutton KG, Baillie DL, et al. Molecular and functional characterization of a family of rat brain T-type calcium channels. J Biol Chem 2001; 276: 3999-4011.
17. Tso JY, Sun XH, Kao T, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehydes-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucleic Acids Res 1985; 13: 2485-2502.
18. 2+ currents in ventricular myocytes from rats with chronic diabetes. Am J Physiol 1995; 269: H1288-H1296.
19. 2+ channels on voltage-dependent facilitation mechanisms. Jpn J Physiol 2001; 51: 337-344.
20. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003; 83: 117-161.
21. Takebayashi S, Li Y, Kaku T, Inagaki S, Hashimoto Y, Kimura K, et al. Remodeling excitation-contraction coupling of hypertrophied ventricular myocytes is dependent on T-type calcium channels expression. Biochem Biophys Res Commun 2006; 345: 766-773.
22. Mulder P, Richard V, Compagnon P, Henry JP, Lallemand F, Clozel JP, et al. Increased survival after long-term treatment with mibefradil. a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997; 29: 416-421.
23. Levine TB, Bernink PJ, Caspi A, Elkayam U, Geltman EM. Greenberg B, et al. Effect of inibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: The MACH-1 Study. Circulation 2000; 101: 758-764.
24. Véniant M, Clozel JP, Heudes D, Banken L, Menard J. Effect of Ro 40-5967, a new calcium antagonist, and enarapril on cardiac remodeling in renal hypertensive rats. J Cardiovasc Pharmecol 1993; 21: 544-551.
25. Clozel JP, Osterrieder W, Kleinblosem CH, Welker HA, Schläppi B, Tudor R, et al. Ro 490-5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991; 9: 4-17.
26. 2+ channel and heart failure. Proc Assoc Am Physicians 1999; 111: 429-437.
27. Po AL, Zhang WY. What lessons can be learnt from withdrawal of inibefradil from the market? Lancet 1998; 351: 1829-1830.